Madrigal Pharmaceuticals Inc (MDGL) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Madrigal Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Madrigal Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Madrigal Pharmaceuticals Inc recorded a cumulative net loss of $-325 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -25.58%.
However, within the Healthcare sector 389 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3554, from total ROA ranking in the first quarter of 2026 at 4166.
Madrigal Pharmaceuticals Strengthens Leadership Team Amid Financial ChallengesIntroductionMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company renowned for its focus on developing novel therapeutics for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), has made significant strides in fortifying its leadership team amidst recent financial challenges. On October 1, 2024, the company welcomed Dr. Michael R. Charlton as their Senior Vice President of Clinical Development. This strategic move comes at a critical juncture as Madrigal navigates a tumultuous financial landscape while striving for innovation in its research and development efforts.Dr. Michael R. Charlton s AppointmentDr. Michael R. Charlton, M.B.B.S. F.R.C.P. brings a wealth of experience and expertise to Madrigal. His role as Senior Vice President of Clinical Development will be pivotal as the company seeks to expedite its clinical trials and enhance the efficacy of its therapeutic agents targeting NASH/MASH. Dr. Charlton s extensive background in clinical research and development positions him as an invaluable asset to Madrigal, especially given the urgency to address the pressing healthcare needs associated with liver diseases.
Madrigal Pharmaceuticals, a prominent biopharmaceutical company striving to develop innovative treatments for nonalcoholic steatohepatitis (NASH), has recently announced the appointment of Shannon Kelley as their new General Counsel. Effective from August 5, 2024, this appointment is expected to bring a fresh perspective and legal acumen to the company. Madrigal Pharmaceuticals has been making significant strides in the healthcare industry, with their stock showing a positive trend and being only 6.8% away from its 52-week high. This speaks volumes about the company s growth potential and investor confidence.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has recently welcomed three key additions to its leadership team, aiming to bolster its pursuit of innovative therapeutics for nonalcoholic steatohepatitis (NASH). The company s latest hires include Mark Barrett as Chief Business Officer, Clint Wallace as Chief Human Resources Officer, and Tina Ventura as Chief Investor Relations Officer. However, these strategic appointments come at a time when Madrigal Pharmaceuticals is grappling with a decline in share prices and a significant net loss. During the 12-month period ending in the third quarter of 2023, Madrigal Pharmaceuticals Inc recorded a cumulative net loss of $-347 million, resulting in a negative return on assets (ROA) of -112.78%. This challenging financial trend has cast a shadow on the company s performance. Moreover, when compared to other companies within the Healthcare sector, a total of 873 firms boasted a higher return on assets, indicating potential areas for improvement.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
